Sulfonamides
"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
Descriptor ID |
D013449
|
MeSH Number(s) |
D02.065.884 D02.886.590.700
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 | 1997 | 0 | 2 | 2 | 1998 | 0 | 1 | 1 | 1999 | 2 | 0 | 2 | 2000 | 2 | 2 | 4 | 2001 | 1 | 2 | 3 | 2002 | 5 | 0 | 5 | 2003 | 4 | 1 | 5 | 2004 | 4 | 2 | 6 | 2005 | 5 | 4 | 9 | 2006 | 7 | 7 | 14 | 2007 | 3 | 3 | 6 | 2008 | 8 | 6 | 14 | 2009 | 5 | 3 | 8 | 2010 | 7 | 3 | 10 | 2011 | 13 | 7 | 20 | 2012 | 9 | 5 | 14 | 2013 | 9 | 6 | 15 | 2014 | 12 | 8 | 20 | 2015 | 9 | 8 | 17 | 2016 | 6 | 7 | 13 | 2017 | 8 | 6 | 14 | 2018 | 9 | 10 | 19 | 2019 | 10 | 5 | 15 | 2020 | 8 | 10 | 18 | 2021 | 2 | 4 | 6 | 2022 | 1 | 7 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovic M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022 08 09; 6(15):4553-4557.
-
Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022 10; 28(10):694.e1-694.e9.
-
Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv. 2022 07 12; 6(13):3879-3883.
-
Blauvelt A, Boguniewicz M, Brunner PM, Luna PC, Biswas P, DiBonaventura M, Farooqui SA, Rojo R, Cameron MC. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 Aug; 33(5):2605-2613.
-
Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clin Cancer Res. 2022 07 01; 28(13):2753-2761.
-
Madhavan K, Balakrishnan I, Lakshmanachetty S, Pierce A, Sanford B, Fosmire S, Elajaili HB, Walker F, Wang D, Nozik ES, Mitra SS, Dahl NA, Vibhakar R, Venkataraman S. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth. Clin Cancer Res. 2022 06 01; 28(11):2409-2424.
-
Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Johnson LA, Rodansky ES, Tran A, Collins SG, Eaton KA, Malamet B, Steiner CA, Huang S, Spence JR, Higgins PDR. Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model. Inflamm Bowel Dis. 2022 02 01; 28(2):161-175.
-
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 12 28; 5(24):5565-5573.
-
Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022 02; 57(2):160-166.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|